Evolus, Inc. Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Global Net Revenue: $73.1 million, a 7% increase year-over-year.

Jeuveau Revenue: $66.4 million, with unit growth and pricing stability.

Evolisse Revenue: $6.7 million.

Adjusted EBITDA: Positive at $0.6 million, improving from a loss of $5.5 million in Q1 2025.

Gross Margin: Reported at 67%, adjusted gross margin at 68%.

Operating Expenses: GAAP operating expenses were $55.7 million; non-GAAP operating expenses were $49.1 million.

Cash Position: $49.8 million in cash and equivalents, with access to an additional $120 million in capital.

2Strategic Updates and Business Highlights

Evolus reported strong momentum from Q4 2025, achieving its second consecutive quarter of positive adjusted EBITDA.

The company maintained a 14% market share for Jeuveau and gained share with Evolisse, supported by a differentiated commercial model and a cash-pay platform.

The Performance Beauty platform integrates customer engagement, product ordering, and consumer loyalty, enhancing operational efficiency.

Evolus is focusing on expanding its product portfolio, with the upcoming launch of Esteem in Europe and expected FDA approval for Sculp in Q4 2026.

The company has seen total purchasing accounts increase by nearly 500, with over 18,000 customers having purchased from Evolus.

3Forward Guidance and Outlook

Evolus expects full-year 2026 revenue of $327 million to $337 million, with adjusted gross margin of 65.5% to 67%.

The company anticipates high single-digit growth for Jeuveau and total company revenue growth of 10% to 13%.

Confidence in achieving full-year adjusted EBITDA profitability remains strong.

4Bad News, Challenges, or Points of Concern

Tariff Risk: A 15% tariff on certain pharmaceutical products from South Korea, effective September 2026, poses a potential challenge, although Evolus is exploring mitigation strategies.

Market Dynamics: The filler market remains flat to slightly down, with ongoing competitive pressures and a need for Evolisse to gain traction against established brands.

Seasonality: Q1 is typically the lowest revenue quarter, and there were one-time revenue deferral dynamics affecting comparisons to the prior year.

5Notable Q&A Insights

Evolisse Launch: While the filler market is experiencing headwinds, the sentiment among clinicians is improving, and Evolisse is gaining confidence and reorder rates as clinics gain experience with the product.

Competitive Landscape: The entry of new competitors like Hugel has not significantly impacted Evolus's market share, which remains stable.

Market Recovery: There are signs of recovery in the aesthetics market, particularly with the influx of GLP-1 patients seeking aesthetic treatments.

Future Product Pipeline: Evolus is actively seeking biostimulator assets and other innovations to enhance its product offerings, with a focus on skin quality and hair treatments. Overall, Evolus demonstrated strong financial performance in Q1 2026, with a positive outlook despite some market challenges and competitive pressures. The company is strategically positioned for growth with its innovative product pipeline and operational efficiencies.